Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Factors Associated with COVID-19 Vaccine Booster Hesitancy: a Retrospective Cohort Study, Fukushima Vaccination Community Survey

Version 1 : Received: 22 February 2022 / Approved: 25 February 2022 / Online: 25 February 2022 (10:01:23 CET)

A peer-reviewed article of this Preprint also exists.

Yoshida, M.; Kobashi, Y.; Kawamura, T.; Shimazu, Y.; Nishikawa, Y.; Omata, F.; Zhao, T.; Yamamoto, C.; Kaneko, Y.; Nakayama, A.; Takita, M.; Ito, N.; Kawashima, M.; Sugiura, S.; Shibuya, K.; Iwami, S.; Kim, K.; Iwanami, S.; Kodama, T.; Tsubokura, M. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines 2022, 10, 515. Yoshida, M.; Kobashi, Y.; Kawamura, T.; Shimazu, Y.; Nishikawa, Y.; Omata, F.; Zhao, T.; Yamamoto, C.; Kaneko, Y.; Nakayama, A.; Takita, M.; Ito, N.; Kawashima, M.; Sugiura, S.; Shibuya, K.; Iwami, S.; Kim, K.; Iwanami, S.; Kodama, T.; Tsubokura, M. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines 2022, 10, 515.

Journal reference: Vaccines 2022, 10, 515
DOI: 10.3390/vaccines10040515

Abstract

This was a retrospective cohort study, which aimed to investigate the factors associated with hesitancy to receive the third dose of coronavirus disease 2019 (COVID-19) vaccine. A paper-based questionnaire survey was administered to all participants. Accordingly, the study included participants who provided answer in the questionnaire whether they have an intent to receive the third dose of vaccine. Data on sex, age, area of residence, adverse reactions after the second vaccination, whether the third vaccination was desired, and reasons to accept or hesitate booster vaccination were retrieved. Among the 2439 participants with mean (±SD) age of 52.6±18.9 years, and median IgG-S antibody titer of 324.9 (AU/mL), 97.9% of participants indicated their intent to accept a third vaccination dose. The logistic regression revealed that younger age (OR=0.98; 95% CI: 0.96-1.00) and higher antibody level (OR=2.52; 95% CI: 1.27-4.99) are positively associated with the third vaccine hesitancy. The efficacy of the COVID-19 vaccine and concerns about adverse reactions had significant impact on the third vaccination behavior. A rapid increase in the booster dose rate is needed to control the pandemic, and specific approaches should be taken in these groups that are likely to hesitate the third vaccine, subsequently increasing booster contact rate.

Keywords

antibody; BNT162b2; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; vaccine hesitancy; vaccine booster

Subject

MEDICINE & PHARMACOLOGY, Allergology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.